Atilla Erden, Yalciner Merih, Atilla Pinar Ataca, Ates Can, Bozdag Sinem Civriz, Yuksel Meltem Kurt, Toprak Selami Kocak, Gunduz Mehmet, Ozen Mehmet, Akan Hamdi, Demirer Taner, Arslan Onder, Ilhan Osman, Beksac Meral, Ozcan Muhit, Gurman Gunhan, Topcuoglu Pervin
Department of Hematology, Ankara University School of Medicine, Ankara, Turkey.
Department of Internal Medicine, Ankara University School of Medicine, Ankara, Turkey.
Antivir Ther. 2018;23(8):647-653. doi: 10.3851/IMP3252.
Haemorrhagic cystitis (HC) is usually a serious complication in allogeneic haematopoietic stem cell transplantation (allo-HSCT) recipients. In this study, our aim was to define risk factors and outcomes for patients with HC in an allo-HSCT setting.
We retrospectively evaluated 249 allo-HSCTs performed between 2011 and 2016 in our centre.
HC was diagnosed in 98 patients (39%) at a median of 119 days (range 5-580) and 91 (93%) of the patients had late onset disease. In univariate analysis, HC was related to cytomegalovirus (CMV) reactivation (P<0.001) and BK viraemia (P<0.001); in multivariate analysis, the presence of CMV reactivation was determined to be an independent risk factor (odds ratio: 22.1; 95% CI 1.73, 282.44; P=0.017). There was no association detected between acute graft versus host disease and patients diagnosed with HC within 100 days of transplant. HC was significantly increased by the presence of myelo-ablative conditioning (odds ratio: 31.28; 95% CI 3.98, 246.87; P=0.001) and BK viraemia (odds ratio: 3.93; 95% Cl 1.10, 14.05; P=0.035) in patients with HC grade II and beyond. Forced hydration was recommended in all patients with grade I HC. Patients with HC and clots were treated with continuous bladder irrigation, and 14 of 44 patients with BK viraemia received cidofovir ± ribavirin. Eight of these patients (57%) responded to treatment. Refractory HC was detected in 17 patients (17%) and resolved by a variety of procedures.
This study suggests that CMV reactivation is associated with increased risk of HC in multivariate analysis, however, this result is not confirmed in patients with HC grade II and beyond.
出血性膀胱炎(HC)通常是异基因造血干细胞移植(allo-HSCT)受者的一种严重并发症。在本研究中,我们的目的是确定allo-HSCT环境下HC患者的危险因素和预后情况。
我们回顾性评估了2011年至2016年在我们中心进行的249例allo-HSCT。
98例患者(39%)被诊断为HC,中位时间为119天(范围5-580天),其中91例(93%)患者为迟发性疾病。单因素分析中,HC与巨细胞病毒(CMV)再激活(P<0.001)和BK病毒血症(P<0.001)相关;多因素分析中,CMV再激活的存在被确定为独立危险因素(比值比:22.1;95%可信区间1.73,282.44;P=0.017)。在移植后100天内诊断为HC的患者中,未检测到急性移植物抗宿主病与HC之间存在关联。对于II级及以上的HC患者,清髓性预处理(比值比:31.28;95%可信区间3.98,246.87;P=0.001)和BK病毒血症(比值比:3.93;95%可信区间1.10,14.05;P=0.035)会显著增加HC的发生风险。所有I级HC患者均建议进行强制水化。HC伴有血凝块的患者接受持续膀胱冲洗治疗,44例BK病毒血症患者中有14例接受了西多福韦±利巴韦林治疗。其中8例患者(57%)对治疗有反应。17例患者(17%)检测到难治性HC,并通过多种程序得到缓解。
本研究表明,多因素分析中CMV再激活与HC风险增加相关,然而,在II级及以上的HC患者中这一结果未得到证实。